The Scleroderma Market was valued at USD 2.5 billion in 2024 and is projected to reach USD 4.1 billion by 2034, registering a CAGR of 5.2%. The growth trajectory of this market is underpinned by several factors, including an increasing prevalence of scleroderma, advancements in treatment modalities, and heightened awareness regarding the disease. Scleroderma, a rare autoimmune disorder...